Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care (The RESPONSE Trial)
Phase of Trial: Phase III
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Ruxolitinib (Primary) ; Hydroxycarbamide
- Indications Polycythaemia vera
- Focus Registrational; Therapeutic Use
- Acronyms RESPONSE
- Sponsors Incyte Corporation
- 02 Mar 2018 Status changed from active, no longer recruiting to completed.
- 25 Feb 2018 As per EudraCT, this trial has been completed in Germany (end date: 2018-02-09).
- 17 Feb 2018 As per EudraCT, this trial has been completed in Belgium (end date: 2018-02-09).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History